Reading the tape
NASDAQ: COGT
Cogent Biosciences, Inc.
Healthcare · Biotechnology
Market Cap
$5.97B
52w High
$43.73
52w Low
$4.55
P/E
-7.00
Volume
29.75K
Outstanding Shares
162.31M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 559.43%FCF (TTM): -27.66%
What changed
The stock rose 559.43% over the last year. Free cash flow declined 27.66% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
A decisive shift in revenue or cash flow over the next period would be the clearest signal to resolve the ambiguity.
Company profile
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases.
CEOAndrew R. Robbins
SectorHealthcare
IndustryBiotechnology
Employees205
IPO dateMar 29, 2018
Valuation
Forward P/E—
EV/EBITDA-7.12
Enterprise value$2.34B
Stock splits
Nov 9, 2020↓ Reverse
Every 4 shares became 1
Profitability & growth
Revenue growth—
Gross margin0%
Operating margin0%
ROE-51.69%▲48.22%vs FY2024
Analyst consensus
RatingBuy
Target price$48.13▲30.82%
10
Buy
2
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 5, 2026
Q2 FY26 · EPS est -$0.53 · Revenue est $500
View